Age

18–95

Sex

MALE

Healthy volunteers

Not accepted

18 years or older
pathologically confirmed high-risk (T3a or Gleason score ≥ 8 or a PSA \> 20 ng/ml) prostate cancer
a WHO performance status 0-1
history of neoadjuvant androgen deprivation therapy(ADT) within 6 months before enrollment
Patients with pelvic positive lymph node were also included in our study

distant metastasis
history of neoadjuvant ADT over 6 months before enrollment
history of definitive treatment for prostate cancer such as radical prostatectomy
history of pelvic irradiation; prostate volume≥100 cm3

A Phase II Clinical Study of Stereotactic Radiation Therapy in Patients With High-risk Prostate Cancer